Cargando…

Bempedoic Acid: for Whom and When

PURPOSE OF REVIEW: The aim of creating an orally active non-statin cholesterol-lowering drug was achieved with bempedoic acid, a small linear molecule providing both a significant low-density lipoprotein cholesterol (LDL-C) reduction and an anti-inflammatory effect by decreasing high-sensitivity C-r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruscica, Massimiliano, Sirtori, Cesare R., Carugo, Stefano, Banach, Maciej, Corsini, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Nonstatin Drugs (L. Tokgozoglu and A.L. Catapano, Section Editors)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474414/ https://www.ncbi.nlm.nih.gov/pubmed/35900636 http://dx.doi.org/10.1007/s11883-022-01054-2

Ejemplares similares

Inclisiran: How Widely and When Should We Use It?
por: Pirillo, Angela, et al.
Publicado: (2022)

Lp(a): a New Pathway to Target?
por: Nurmohamed, Nick S., et al.
Publicado: (2022)

PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2022)

Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
por: Cicero, Arrigo F. G., et al.
Publicado: (2021)

New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
por: Bilen, Ozlem, et al.
Publicado: (2016)

The Role of High-Density Lipoprotein Cholesterol in 2022
por: Sirtori, Cesare R., et al.
Publicado: (2022)

PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
por: Carugo, Stefano, et al.
Publicado: (2022)

Lipid Lowering Drugs: Present Status and Future Developments
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
por: Penson, Peter E., et al.
Publicado: (2020)

RNA Silencing in the Management of Dyslipidemias
por: Henney, Neil C., et al.
Publicado: (2021)

Best Practices for Data Sharing in Phylogenetic Research
por: Cranston, Karen, et al.
Publicado: (2014)

Arbor: Comparative Analysis Workflows for the Tree of Life
por: Harmon, Luke J., et al.
Publicado: (2013)

Next-generation phenomics for the Tree of Life
por: Burleigh, J. Gordon, et al.
Publicado: (2013)

The Ideas Lab Concept, Assembling the Tree of Life, and AVAToL
por: Collins, Timothy, et al.
Publicado: (2013)

Clinical approach to the inflammatory etiology of cardiovascular diseases
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid
por: Ferri, Nicola, et al.
Publicado: (2023)

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
por: Fruchart, Jean-Charles, et al.
Publicado: (2020)

Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
por: Stefanutti, Claudia
Publicado: (2020)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?
por: Parhofer, Klaus G.
Publicado: (2021)

Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
por: Visser, Jolien, et al.
Publicado: (2022)

Multinévrite oculaire dans le cadre d’une infection COVID-19
por: Raharimanantsoa, O.L., et al.
Publicado: (2020)

Centenaire après 50 années de diabète de type 2
por: Levart, Eugène, et al.
Publicado: (2020)

Influence de la « phobie du COVID » sur les diagnostics oto-rhino-laryngologiques précoces()
por: Sideris, G., et al.
Publicado: (2020)

Surdité brusque et SARS-CoV-2 : n’oublions pas le bilan standard !()
por: Guigou, C., et al.
Publicado: (2021)

Les injections intravitrennes au CHU de Caen durant l’épidémie de SARS-COV2
por: Delbrayelle, S., et al.
Publicado: (2021)

Republication de : The Bedside Clinical Examination as a key element of the swallowing assessment during the COVID 19 Pandemic()
por: Longo, L., et al.
Publicado: (2021)

Republication de : COVID-19 patient with recurrent anosmia and its impact on management()
por: Rizki, N.A., et al.
Publicado: (2022)

Association de la metformine au meilleur pronostic chez les patients diabétiques hospitalisés pour la COVID-19 : le bénéfice tiendrait à la continuation de la metformine durant le séjour hospitalier
por: Lalau, Jean-Daniel, et al.
Publicado: (2022)

Republication de : Hide and seek epistaxis after COVID-19 infection()
por: Soloperto, D., et al.
Publicado: (2022)

Quotidien de vie des patients avec cancer des VADS pendant la période COVID
por: Babin, E., et al.
Publicado: (2022)

Perforation cornéenne sur ulcère de Mooren en post-vaccination anti-COVID-19 : à propos d’un cas
por: Alliti, F., et al.
Publicado: (2023)

Délai opératoire après infection Covid : évolution des recommandations de la Société française d’anesthésie et de réanimation()
por: Vellin, J.-F., et al.
Publicado: (2022)

Brain Imaging in Gambling Disorder
por: Quester, Saskia, et al.
Publicado: (2015)

Analysis of Social Communication Questionnaire (SCQ) Screening for Children Less Than Age 4
por: Marvin, Alison R., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0u4fcqf751a12b4dj5nld3svfk